CPI Combination Therapy for Autoimmune Encephalitis
Key facts
- Who runs it
- Xuanwu Hospital, Beijing
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 70 people enrolled
- Started
- 25 Nov 2020
- Ended
- 12 Sept 2024
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Plasma exchange (PE)
- intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
- Record updated
- 27 June 2025
Who can take part
- Age
- 14 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (11)Hide the full registry criteria
Who can take part
- 14-65 years old
- met all the three following diagnostic criteria of AE: (i) subacute onset (rapid progress of less than 3 months) of working memory deficits, altered mental status, or psychiatric symptoms; (ii) at least one of the followings: new focal CNS findings, seizures not explained by a previously known disease, cerebrospinal fluid (CSF) pleocytosis (white blood cell count 5 cells/mm3), magnetic resonance imaging (MRI) features suggestive of encephalitis, and (iii) reasonable exclusion of alternative causes
- the presence of antibody against neuronal surface antigen in serum or CSF indicating a positive diagnosis of AE using a cell-based assay
- critically ill with a modified Rankin scale (mRS) score of 4 to 5
- within 3 months of onset
- no immunotherapy previously
Who cannot take part
- relative contraindications of TPE treatment: serious underlying diseases such as severe active hemorrhage, disseminated intravascular coagulation, severe hypotension or shock, unstable cardiac failure, cerebral herniation, severe infection or other endangered conditions
- allergic to immunoglobulin
- contraindications of glucocorticoid therapy: glucocorticoid allergy, active gastric or duodenal ulcer, severe osteoporosis, diabetes, hypertension after recent gastrointestinal anastomosis, and serious infection that cannot be controlled by antibiotics
- serious underlying diseases, such as cardiac dysfunction, arrhythmia, and coagulation disorders
- premorbid mRS ≥ 3
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Corticosteroids, intravenous immunoglobulin (IVIG), and plasma exchange (PE) are the first-line therapies for autoimmune encephalitis (AE) patients, but optimal first-line treatment strategy for different AE patients remains undetermined. The study is to compare the efficacy between pulse corticosteroid plus PE initially followed by IVIG (CPI therapy) and pulse corticosteroid plus IVIG followed by PE two weeks later (CIP therapy) in patients with severe antibody-associated autoimmune encephalitis (AE).
The 2 groups in the trial
- CPI groupTreatment being tested
Intravenous methylprednisolone (IVMP) combined with PE (5 times in each course) and IVIG after PE.
Treatment: Plasma exchange (PE) and intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
- CIP groupExisting treatment, for comparison
IVMP and IVIG (0.4g/kg/d for 5 days) immediately, followed by PE at least 2 weeks after IVIG treatment.
Treatment: Plasma exchange (PE) and intravenous immunmoglobulin (IVIG), intravenous methylprednisolone (IVMP)
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Combination Therapy of Pulse Corticosteroid and Plasma Exchange Followed by Intravenous Immunoglobulin in Patients With Severe Antibody- Associated Autoimmune Encephalitis: a Randomized Controlled Trial
- Record updated
- 27 June 2025